For decades, researchers have pursued an ambitious idea: What if a vaccine could teach a patient’s immune system to recognize their unique cancer?

A positive Phase 3 topline readout suggests that vision may be moving closer to reality.

Merck and Moderna recently announced positive results from a Phase 3 clinical trial evaluating intismeran autogene, an individualized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda®) for patients with high-risk melanoma whose tumors had been completely removed by surgery.

The combination significantly extended the time patients went without their cancer returning, known as recurrence-free survival, compared with Keytruda alone. It also significantly improved distant metastasis-free survival, meaning patients went longer without their cancer returning in another part of the body.

These results represent the first positive Phase 3 trial of an individualized neoantigen therapy and an mRNA-based cancer therapy — an important milestone for a field that scientists have been advancing for decades.

How Does a Personalized mRNA Cancer Vaccine Work?

Unlike vaccines that prevent infectious diseases, intismeran is a therapeutic cancer vaccine: it is designed to help treat cancer rather than prevent it from developing in the first place.

And unlike a one-size-fits-all vaccine, each patient’s therapy is designed specifically for that patient.

Researchers begin with a sample of the patient’s tumor and analyze its genetic mutations. Some of those mutations can create unique markers, called neoantigens, that are found on cancer cells but not normal cells.

Scientists then select neoantigens unique to that patient’s cancer and encode them in mRNA, a temporary set of instructions that help show the immune system what to target.

In effect, the vaccine gives the immune system a personalized guide to identifying the patient’s cancer.

But recognizing cancer is only part of the challenge.

Tumors can exploit natural immune checkpoints — mechanisms that normally prevent immune responses from becoming too strong — to suppress T cells, immune cells that recognize and destroy abnormal cells. Keytruda blocks one of these checkpoints, called PD-1, helping T cells maintain their response against cancer.

In essence, the vaccine helps show the immune system what to target; Keytruda helps it sustain that response.

Two Paths in Cancer Immunotherapy Converge

For the Cancer Research Institute (CRI), this milestone has particular resonance.

Long before cancer immunotherapy became a pillar of modern oncology, CRI was investing in the fundamental science needed to understand how the immune system recognizes and responds to cancer.

Cancer vaccines have been part of that story from the beginning.

In the 1950s, CRI’s founding scientific and medical director, Lloyd J. Old, MD, helped demonstrate that the tuberculosis vaccine Bacillus Calmette-Guérin (BCG) could stimulate an immune response against tumors in mice. Decades later, BCG became the first active immunotherapy approved by the U.S. Food and Drug Administration (FDA) for cancer.

Dr. Old spent much of his career pursuing another idea: that scientists could identify features unique to cancer cells and use them to direct an immune response against tumors.

In 2001, CRI and the Ludwig Institute for Cancer Research established the Cancer Vaccine Collaborative, a global academic network designed to accelerate the development and testing of therapeutic cancer vaccines. Over its first decade, the CVC conducted nearly 60 early-phase trials. Its researchers studied not only which cancer targets could generate an immune response, but also what additional signals might be needed to make those responses stronger and more durable.

At the same time, another revolution in cancer immunology was taking shape.

CRI began funding research in the laboratory of James P. Allison, PhD, in 1992. His discoveries helped establish that blocking immune checkpoints could release the natural “brakes” on T cells and enable them to respond more effectively to cancer. His work ultimately helped launch checkpoint blockade as an entirely new approach to cancer treatment and earned him the 2018 Nobel Prize in Physiology or Medicine.

CRI also recognized the foundational work behind mRNA-based therapies. In 2021, CRI awarded the William B. Coley Award to Katalin Karikó, Drew Weissman, Uğur Şahin, and Özlem Türeci for pivotal contributions to mRNA-based approaches in cancer and infectious disease. Karikó and Weissman later received the 2023 Nobel Prize in Physiology or Medicine for discoveries that enabled effective mRNA vaccines against COVID-19.

Today, all of these scientific paths are converging.

An individualized cancer vaccine can give the immune system information about what to recognize. Checkpoint blockade can help create the conditions for immune cells to respond and persist.

It is a combination that brings together two areas of cancer immunology that CRI has helped advance for decades.

The positive results reported in INTerpath-001 offer the strongest late-stage evidence to date that combining these concepts may improve outcomes for patients.

What Did the Phase 3 Trial Find?

The global Phase 3 INTerpath-001 trial enrolled 1,137 patients with stage IIB–IV cutaneous melanoma whose tumors had been completely removed through surgery.

After surgery, patients received either intismeran plus Keytruda or Keytruda alone, with the goal of reducing the risk that their cancer would return.

At a planned interim analysis, the companies reported that the combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone.

The magnitude of benefit in the Phase 3 trial has not yet been disclosed. In the smaller Phase 2b trial, five-year follow-up showed that the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with Keytruda alone.

What Happens Next?

As exciting as these findings are, there is still much to learn.

Intismeran remains investigational and has not been approved for routine use. Merck and Moderna have so far announced topline Phase 3 results, and detailed data have not yet been presented publicly. The trial is also continuing to evaluate other outcomes, including overall survival, which will help researchers understand whether the combination ultimately helps patients live longer.

There are practical questions, too. Because intismeran is individualized, every patient’s tumor must be analyzed and a vaccine manufactured specifically for them. If personalized cancer vaccines become part of routine care, researchers and health systems will need to address the time, infrastructure, access, and cost involved in producing them at scale.

And melanoma is only one piece of the story.

Intismeran is being studied in several other cancers, and researchers around the world are investigating different vaccine technologies, tumor targets, and combination treatments. Future studies will help determine how broadly individualized cancer vaccines can benefit patients.

Decades of Discovery, a New Chapter

Scientific breakthroughs rarely begin with a single experiment.

They are built over years — sometimes decades — as one discovery makes another possible.

The idea that the immune system could recognize cancer was once controversial. So was the idea of releasing immune checkpoints to enable T cells to respond to tumors. So was the possibility of identifying mutations unique to an individual’s cancer and creating a vaccine specifically for that patient.

Today, those ideas are coming together in a Phase 3 clinical trial.

That is why CRI has invested in cancer immunology for more than 70 years: to identify and support exceptional science early, give researchers the resources to pursue bold ideas, and build the knowledge that can ultimately lead to better treatments for patients.

The positive results from INTerpath-001 do not mark the end of the cancer vaccine story.

They mark the beginning of an important new chapter.